标题
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 10, Pages 2111
出版商
MDPI AG
发表日期
2017-10-09
DOI
10.3390/ijms18102111
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF
- (2017) Jiyeon Choi et al. NATURE GENETICS
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach
- (2017) Salete J. Baptista et al. PLoS One
- A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
- (2016) J.K. Litton et al. ANNALS OF ONCOLOGY
- PARP inhibitors in ovarian cancer
- (2016) J. A. Ledermann ANNALS OF ONCOLOGY
- PARP inhibitors: the race is on
- (2016) Jessica S Brown et al. BRITISH JOURNAL OF CANCER
- Design, Synthesis, and Biological Evaluation of Some Cyclohepta[b]Thiophene and Substituted Pentahydrocycloheptathieno[2,3-d]Pyrimidine Derivatives
- (2016) Elshaymaa I. Elmongy et al. JOURNAL OF HETEROCYCLIC CHEMISTRY
- Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors
- (2016) Monica E. Wielgos et al. MOLECULAR CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair
- (2016) E-B Choi et al. ONCOGENE
- DNA repair targeted therapy: The past or future of cancer treatment?
- (2016) Navnath S. Gavande et al. PHARMACOLOGY & THERAPEUTICS
- Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation
- (2016) B. A. Gibson et al. SCIENCE
- PARP-1 may be involved in angiogenesis in epithelial ovarian cancer
- (2016) Wei Wei et al. Oncology Letters
- Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
- (2016) Florian Engert et al. Oncotarget
- Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer
- (2016) Leilei Fu et al. Scientific Reports
- Functions of PARylation in DNA Damage Repair Pathways
- (2016) Huiting Wei et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres
- (2015) Torun Ekblad et al. Chemical Biology & Drug Design
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib
- (2015) K. Lin et al. EUROPEAN JOURNAL OF CANCER
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
- (2015) Felix Y. Feng et al. MOLECULAR CELL
- Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
- (2015) Sebastian Eustermann et al. MOLECULAR CELL
- Nuclear PARP1 expression and its prognostic significance in breast cancer patients
- (2015) Annalisa Mazzotta et al. TUMOR BIOLOGY
- Profile of veliparib and its potential in the treatment of solid tumors
- (2015) Lars Wagner OncoTargets and Therapy
- Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
- (2014) Barbara Lupo et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
- (2014) K. A. Reiss et al. CLINICAL CANCER RESEARCH
- Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3
- (2014) Carole Beck et al. EXPERIMENTAL CELL RESEARCH
- PARP Inhibitors as P-glyoprotein Substrates
- (2014) Denise Lawlor et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Transcriptional Roles of PARP1 in Cancer
- (2014) Matthew J. Schiewer et al. MOLECULAR CANCER RESEARCH
- Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up
- (2014) PIOTR DONIZY et al. ONCOLOGY REPORTS
- Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
- (2014) Marine Gilabert et al. PLoS One
- Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors
- (2013) Qihua Zhu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer
- (2013) J. D. Steffen et al. CANCER RESEARCH
- PARP expression in germ cell tumours
- (2013) Michal Mego et al. JOURNAL OF CLINICAL PATHOLOGY
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- PARP-1 and gene regulation: Progress and puzzles
- (2013) W. Lee Kraus et al. MOLECULAR ASPECTS OF MEDICINE
- The complexity of NF-κB signaling in inflammation and cancer
- (2013) Bastian Hoesel et al. Molecular Cancer
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
- (2013) M. Ihnen et al. MOLECULAR CANCER THERAPEUTICS
- PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation
- (2013) María Isabel Rodríguez et al. PLoS Genetics
- PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
- (2013) Amanda Swindall et al. Cancers
- Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
- (2013) Alice N. Weaver et al. Frontiers in Oncology
- HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair
- (2012) S. Nowsheen et al. CANCER RESEARCH
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- PARP-1 protein expression in glioblastoma multiforme
- (2012) A. Galia et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Potential Role of Poly(ADP-Ribose) Polymerase (PARP) Activation in Methotrexate-Induced Nephrotoxicity and Tubular Apoptosis
- (2012) Selvinaz Dalaklioglu et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
- (2012) Ammar A E Ali et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
- (2012) M.-F. Langelier et al. SCIENCE
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
- (2011) Pawel Domagala et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Structural studies of the PARP-1 BRCT domain
- (2011) Paul A Loeffler et al. BMC STRUCTURAL BIOLOGY
- Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
- (2010) Daniele Santini et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
- (2009) Gianluca Papeo et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression
- (2009) Rosa Quiles-Perez et al. HEPATOLOGY
- Global Analysis of Transcriptional Regulation by Poly(ADP-ribose) Polymerase-1 and Poly(ADP-ribose) Glycohydrolase in MCF-7 Human Breast Cancer Cells
- (2009) Kristine M. Frizzell et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP1 expression in pediatric central nervous system tumors
- (2009) Valerie N. Barton et al. PEDIATRIC BLOOD & CANCER
- Domain C of Human Poly(ADP-ribose) Polymerase-1 Is Important for Enzyme Activity and Contains a Novel Zinc-Ribbon Motif†,‡
- (2008) Zhihua Tao et al. BIOCHEMISTRY
- Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation
- (2008) W Lee Kraus CURRENT OPINION IN CELL BIOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now